COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 may slow disease progression and decrease the severity of symptoms

If you meet the following three criteria, you may be eligible for the study. Participate! Help us!

  1. Positive in COVID-19
  2. Age ≥ 50 years
  3. Symptomatic
Dr. Oriol Mitjà, comments on the COnV-ert study aimed at reducing COVID-19 symptoms and disease severity.


If you have any questions, please contact the researchers by calling 634 755 945 or sending an e-mail to

Description of the Study:

  • Title: Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients.
  • Principal Investigators: Oriol Mitjà and Bonaventura Clotet.
  • Centers of Implementation: Centers in the health region of Bages-Berguedà, Barcelona, Metropolitan South and Metropolitan North. In Catalunya Central, people who meet the requirements will be treated at CUAP Bages and in the Emergency Room of the Hospital Sant Bernabé de Berga.
  • Study Population: People with 50 years of age or older who have had a positive COVID-19 result by PCR or rapid antigen test and who have symptoms not requiring hospitalization for less than 7 days.
  • Study type: Double-blind, Randomized, Prospective Clinical Trial.
  • Design: Randomized study, in which there will be two treatment groups that, in addition to the therapy prescribed by their medical professional for COVID-19, will receive either convalescent plasma or placebo. Assignment to one group or the other will be randomized. It is also a double-blind study in which neither the research team nor the participant will know to which group the latter belongs.
  • Methods: The two treatments (convalescent plasma and placebo) will be administered by intravenous infusion of about 30-40 minutes of duration in a hospital setting. Administration will be performed on the first day of the study, after checking blood group compatibility.

Objectives of the Study:

Principal Objective: To evaluate the efficacy and safety of convalescent plasma treatment in people over 50 years of age with mild to moderate COVID-19 disease who are not hospitalized.

More about this Study:

Scientific context: Coronavirus disease 2019 (COVID-19) is a respiratory infection caused by the SARS-CoV-2 virus. The uncontrolled spread of the SARS-CoV-2 coronavirus has generated an unprecedented health emergency that requires the urgent development of new strategies to protect the population, mainly those most at risk.

Convalescent plasma is given by persons who have passed COVID-19 and contain antibodies against the SARS-CoV-2 virus.

Plasma therapy has been used to treat many conditions and is safe. Convalescent plasma therapy could be very useful for the entire population, mainly for those who are older or have risk factors for developing complications of COVID-19.

Unnamed 1

Other Clinical Trials:

Un bain de bouche antiviral et COVID-19

L’utilisation d’un bain de bouche contenant de la β-cyclodextrine et du citrox (bioflavonoïdes) (CDCM), disponible en pharmacie, permet de réduire la charge virale du SRAS-CoV-2 dans la salive.

Influence du sexe sur les anticorps neutralisants contre le SARS-CoV-2

Cette étude vise à déterminer les différences dans l’évolution de la réponse immunitaire dans les mois qui suivent l’infection par le SARS-CoV-2 chez les hommes et les femmes.


COVIDAir : une nouvelle technologie pour détecter les patients COVID-19

Cette étude vise à déterminer la validité d’une nouvelle méthode de détection du COVID-19 par la caractérisation des molécules présentes dans l’air expiré.

ANTICOV Study : COVID-19 en Afrique

Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.

Progestérone pour traiter le COVID-19

Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la progestérone dans le traitement de COVID-19 chez les hommes hospitalisés.

Flower 729514 1920

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.


Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of Vaxcevria vaccine (AstraZeneca).

Blood Filter for the Treatment of COVID-19

Is removing SARS-CoV-2 from the blood sufficient to decrease the severity of critically ill COVID patients? This clinical trial aims to test the efficacy of a new blood filter for the treatment of COVID-19.

Pediatric COVID vaccination clinical trial

This pediatric clinical trial aims to test the safety, tolerability and immunogenicity of Pfizer’s COVID vaccine in children under 12 years of age.